# Rectal Indomethacin as Early Treatment for Acute Pancreatitis (INDOMAP Trial)

> **NCT03547232** · PHASE4 · RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 1504 (estimated)

## Conditions studied

- Acute Pancreatitis
- Complication
- Mortality Rate
- Organ Failure, Multiple

## Interventions

- **DRUG:** Indomethacin SR
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT03547232
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-01
- **Primary completion:** 2028-06-01
- **Final completion:** 2028-12-01
- **Target enrollment:** 1504 (ESTIMATED)
- **Last updated:** 2025-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03547232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03547232, "Rectal Indomethacin as Early Treatment for Acute Pancreatitis (INDOMAP Trial)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03547232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*